Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.
Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Pozniak AL; NEAT022 Study Group*.
Gatell JM, et al. Among authors: assoumou l.
AIDS. 2017 Nov 28;31(18):2503-2514. doi: 10.1097/QAD.0000000000001675.
AIDS. 2017.
PMID: 29112070
Free PMC article.
Clinical Trial.